ProSciento operates the leading specialized clinical research organization for metabolic diseases in Chula Vista, housing a 30,000-square-foot research unit at 855 Third Avenue with 30-plus treatment beds and 15-plus dedicated glucose clamp stations. Study participants enrolled in obesity, Type 2 diabetes, and MASLD/MASH trials receive investigational therapies compounded on-site in a USP 797/800 clean room, with laboratory work processed through the facility's own CLIA-certified lab rather than through external dispensaries — a self-contained approach distinct from community pharmacies such as Chula Vista Pharmacy. Founded in 2003 and headquartered on the Third Avenue corridor, ProSciento has completed more than 425 clinical research trials for small and large molecule therapies, biologics, biosimilars, and medical devices targeting the metabolic continuum. A proprietary database of 180,000-plus participants — each profiled with over 200 metabolic characterization data points — drives enrollment feasibility assessments that outpace conventional site-network models for early-phase study recruitment. Diagnostic capabilities on the Third Avenue campus complement the acute-care infrastructure at nearby Sharp Chula Vista Medical Center, positioning the CRU within the Medical Center Drive corridor's concentration of clinical resources. Highest-complexity protocols include hyperinsulinemic-euglycemic glucose clamp procedures, hepatic MRI-PDFF fat-fraction imaging, stable-isotope tracer studies for glucose kinetics, and continuous glucose monitoring system validation — all executed under around-the-clock on-site physician oversight.